Abstract Library

#4252 Intra-arterial Peptide Receptor Radionuclide Therapy in a Filipino male with predominantly hepatic metastasis in a known primary pancreatic neuroendocrine tumor

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) has shown positive clinical outcomes in somatostatin receptor (SSTR) overexpressing positive well-differentiated neuroendocrine tumors in combination with somatostatin analogue therapy. A noted decreased progression-free survivability in the use of PRRT has been noted in larger lesions (>3cm).

Conference:

Presenting Author: Azarraga C

Authors: Azarraga C, Leogardo D, Bandong I, Bautista-Peñalosa P,

Keywords: neuroendocrine, PRRT, intra-arterial, bulky,

#3798 Intra-arterial PRRT – A prospective clinical study in NET patients with hepatic metastases

Introduction: Liver metastases of neuro-endocrine tumors have a significant impact on survival of patients treated with 177Lu-DOTATATE.

Conference:

Presenting Author:

Authors: Ebbers S, Barentsz M, de Vries-Huizing D, Versleijen M, Klompenhouwer L,

Keywords: PRRT, intra-arterial, lutetium, neuroendocrine tumor, peptide receptor radionuclide therapy, treatment response,

#1894 Survival Analysis after i.a. 90Y-DOTATATE PRRT, in Patients with Non-Resectable, Advanced, Progressive, Liver-Dominant Neuroendocrine Neoplasms

Introduction: A

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Nowicki M, Kolasińska-Ćwikła A, Lewczuk A, Sankowski A, Bodei L,

Keywords: intra-arterial PRRT, progressive GEP-NENs, liver dominant,